The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2024

Filed:

Dec. 20, 2019
Applicant:

Merus N.v., Utrecht, NL;

Assignee:

Merus N.V., Utrecht, NL;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/28 (2015.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 35/28 (2013.01); A61P 35/00 (2018.01); C07K 16/2851 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01);
Abstract

The disclosure relates to means and methods of treating a subject for a CLEC12A positive cancer. In some embodiments the method comprises treating the subject in need thereof with two or more administrations of a bispecific antibody that binds CD3 and CLEC12A, wherein in a first administration an first amount of the bispecific antibody is administered and wherein in each of the subsequent administrations the amount of bispecific antibody is higher than the amount of bispecific antibody in the first administration. In some embodiments CLEC12A positive cancer treatment methods are provided at intervals and dosing regimens that spare hemopoietic stem cell compartment allowing for recovery of normal CLEC12A positive hemopoietic cells.


Find Patent Forward Citations

Loading…